Mutual of America Capital Management LLC Sells 6,586 Shares of Bruker Co. (NASDAQ:BRKR)

Mutual of America Capital Management LLC lessened its position in Bruker Co. (NASDAQ:BRKR) by 10.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 57,398 shares of the medical research company’s stock after selling 6,586 shares during the period. Mutual of America Capital Management LLC’s holdings in Bruker were worth $4,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Bruker by 4.5% during the first quarter. Vanguard Group Inc. now owns 11,253,314 shares of the medical research company’s stock worth $723,588,000 after purchasing an additional 487,688 shares during the period. BlackRock Inc. boosted its holdings in shares of Bruker by 2.7% during the 1st quarter. BlackRock Inc. now owns 11,135,940 shares of the medical research company’s stock worth $716,042,000 after buying an additional 291,386 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Bruker by 8.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 7,840,735 shares of the medical research company’s stock valued at $488,478,000 after buying an additional 594,362 shares during the last quarter. RTW Investments LP raised its holdings in Bruker by 14.3% in the 3rd quarter. RTW Investments LP now owns 3,381,703 shares of the medical research company’s stock valued at $210,680,000 after acquiring an additional 422,100 shares during the period. Finally, State Street Corp raised its holdings in Bruker by 2.2% in the 1st quarter. State Street Corp now owns 3,308,939 shares of the medical research company’s stock valued at $260,877,000 after acquiring an additional 71,574 shares during the period. 79.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on BRKR shares. The Goldman Sachs Group upped their target price on Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. raised Bruker from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $60.00 to $90.00 in a report on Wednesday, February 14th. UBS Group lifted their target price on Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Stifel Nicolaus upped their price target on shares of Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a research note on Wednesday, February 14th. Finally, Wells Fargo & Company began coverage on shares of Bruker in a research note on Tuesday, December 19th. They issued an “equal weight” rating and a $72.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $84.86.

Insider Activity

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the transaction, the director now owns 23,147 shares of the company’s stock, valued at $2,084,618.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 28.20% of the company’s stock.

Bruker Stock Down 2.2 %

BRKR stock opened at $83.89 on Wednesday. Bruker Co. has a 52 week low of $53.79 and a 52 week high of $94.86. The business has a 50-day simple moving average of $87.24 and a 200 day simple moving average of $73.76. The company has a quick ratio of 0.99, a current ratio of 1.80 and a debt-to-equity ratio of 0.83. The company has a market cap of $11.55 billion, a PE ratio of 28.73, a price-to-earnings-growth ratio of 2.22 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, February 13th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. The company had revenue of $844.50 million during the quarter, compared to analysts’ expectations of $809.35 million. Bruker had a net margin of 14.41% and a return on equity of 29.94%. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.74 EPS. Sell-side analysts anticipate that Bruker Co. will post 2.74 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.24%. The ex-dividend date was Thursday, February 29th. Bruker’s payout ratio is presently 6.85%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.